Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 84,894 Shares of Stock

October 30, 2026 by InsiderTrades.com

Key Points

Major shareholder Qiming sold 84,894 Alamar shares at an average price of $31.39, generating approximately $2.66 million. The sale reduced its position by 33.84% to 165,953 shares, following a broader series of sales totaling roughly 1.2 million shares in October.
Alamar shares opened at $34.04, near the upper end of their 52-week range, while the company reported a quarterly loss of $0.22 per share—better than the expected $0.36 loss—and revenue of $29.43 million.
Analyst sentiment is mixed: JPMorgan and Stifel raised price targets and maintained positive ratings, while Weiss downgraded the stock to sell. The overall consensus is “Hold,” with an average price target of $31.80.

Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 84,894 shares of the firm's stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $31.39, for a total value of $2,664,822.66. Following the completion of the transaction, the insider owned 165,953 shares in the company, valued at $5,209,264.67. This represents a 33.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total value of $3,304,428.49.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.02, for a total transaction of $3,674.72.
On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Trading Down 0.8%

NASDAQ ALMR opened at $34.04 on Friday. The business has a fifty day moving average price of $30.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.85 and a quick ratio of 10.23. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61.

Alamar Biosciences (NASDAQ:ALMR - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million for the quarter. Equities research analysts forecast that Alamar Biosciences, Inc. will post -1.22 EPS for the current year.

Analyst Ratings Changes

ALMR has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an "overweight" rating in a research note on Tuesday, August 11th. Weiss Ratings downgraded Alamar Biosciences from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, October 23rd. Stifel Nicolaus upped their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $31.80.

View Our Latest Analysis on ALMR

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: Strong ALS study validates Alamar’s technology. Emory researchers reported that a 10-protein blood signature detected ALS with 98.3% accuracy and outperformed a leading individual biomarker, including in difficult-to-diagnose cases. Publication in Nature Communications could improve the visibility and commercial credibility of Alamar’s NULISA proteomics platform. Alamar Biosciences' Protein Signature Detects ALS With 98.3% Accuracy in Study
Neutral Sentiment: Analyst views remain mixed. Earlier upgrades from Stifel and JPMorgan set price targets of $32 and $35, respectively, while Weiss Ratings downgraded the stock to sell. The broader analyst consensus is “Hold,” with an average target of $31.80, below the company’s recent trading range. Alamar remains unprofitable, although its latest quarterly loss was narrower than expected and revenue totaled $29.43 million.
Negative Sentiment: Major shareholder Qiming continued a substantial selling program. Corporate GP VI Ltd. Qiming sold 100,837 shares on October 28 and 84,894 shares on October 27, following additional sales on October 26 and earlier dates. Across the reported transactions from October 15 through October 28, the shareholder sold approximately 1.2 million shares, reducing its position to 164,191 shares. The repeated insider-related selling may weigh on sentiment and suggests a significant near-term supply overhang. Alamar Biosciences SEC Insider Sale Filing

Institutional Investors Weigh In On Alamar Biosciences

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alamar Biosciences in the 3rd quarter worth about $196,000. Squarepoint Ops LLC purchased a new stake in Alamar Biosciences during the second quarter worth about $283,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company's stock worth $2,280,000 after buying an additional 10,461 shares during the last quarter. State Street Corp purchased a new stake in Alamar Biosciences during the second quarter worth about $3,930,000. Finally, Wellington Management Group LLP bought a new stake in Alamar Biosciences in the second quarter worth about $12,407,000.

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.